CYP19A1 and breast cancer: However, Chiofalo et al. conducted a study in 2020 to examine the risk of EC among BC survivors taking aromatase inhibitors, tamoxifen, or receiving no treatment at all, and the results indicate that tamoxifen users did not seem to have a higher risk of EC compared to aromatase inhibitor users or those who did not receive treatment.13